Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 6.60, indicating a potential upside of 33.9% from the current price of HKD 4.93 [3][6]. Core Insights - The company's 1H25 performance met expectations, with revenue increasing by 34.6% year-on-year to RMB 47.57 billion, driven by a 34.2% increase in real estate development revenue [3][4]. - The company is projected to exceed annual sales of RMB 120 billion, with a contract sales increase of 11% year-on-year to RMB 61.5 billion in the first half of 2025, achieving 51% of the annual sales target [3][4]. - The financing cost has decreased, with an average financing cost down by 41 basis points to 3.16%, and further reductions are expected in the second half of the year [3]. Financial Performance Summary - Revenue for 1H25 reached RMB 47.57 billion, with real estate development and management revenues at RMB 44.03 billion and RMB 1.61 billion, respectively [3][4]. - Core net profit decreased by 12.7% year-on-year to RMB 1.52 billion, aligning with previous forecasts [3][4]. - The gross profit margin fell by 3.1 percentage points to 10.6%, slightly below the predicted range of 12%-13% [3][4]. Sales and Market Position - The company has a total of RMB 2.35 trillion in saleable resources, with over RMB 400 billion expected to be recognized in the second half of 2025 [3]. - As of June 2025, the company had RMB 1.49 trillion in sold but unrecognized revenue, with approximately 29% and 38% located in the Greater Bay Area and East China, respectively [3]. Debt and Liquidity - Operating cash inflow for the first half of 2025 was approximately RMB 4.1 billion, with total borrowings remaining stable at RMB 103.9 billion [3][4]. - The net debt ratio slightly decreased by 1.4 percentage points to 40.3% as of June 2025 [3][4].

证券研究报告 | 2025年08月27日 绿城中国（03900.HK） 优于大市 结算和计提节奏导致盈利承压，销售拿地仍优于行业平均 归母净利润同减近九成。2025 上半年公司实现营业收入 533.7 亿元，同比下 降 23.5%；归母净利润 2.1 亿元，同比下降 89.7%。公司收入下降的原因主 要是上下半年结转节奏分布不均匀，公司归母净利润下降的主要原因是计提 资产减值及公允价值约 20 亿元（2024 年共 49 亿元）。 销售拿地优于行业平均。2025 上半年公司实现总销售面积 535 万平方米，同 比下降 10%；实现总销售金额 1222 亿元，同比下降 3%，位居全行业 TOP2， 公司销售增速显著优于行业平均水平。在公司的操盘销售中，自投销售 803 亿元，归属公司权益金额为 539 亿元。上半年，公司首开高效，溢价凸显， 其中上海潮鸣东方整盘溢价预计 6.5 亿元，利润率较交底水平提升 7.6pct。 公司聚焦高能级城市，一、二线销售额占比高达 86%，回款率达 94%，继续 维持高位。分区域看，公司长三角区域占销售总额的 69%。 2025 上半年公司新增项目 35 个，新增建面 355 ...

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings [11] Core Views - H&H International Holdings reported a revenue increase of 4.9% year-on-year for H1 2025, with adjusted comparable net profit rising by 4.6%, aligning with previous guidance [11] - The company is expanding its ANC business through online channels and overseas markets, solidifying its industry-leading position, while the BNC business is improving with a rise in ultra-premium infant formula market share [11] - Despite pressure on apparent profits, the company is optimizing its capital structure, which is expected to accelerate debt reduction in the future [11] Financial Performance - For H1 2025, the company achieved a revenue of 7.019 billion yuan, a year-on-year increase of 4.9%, and an adjusted comparable net profit of 363 million yuan, a year-on-year increase of 4.6% [5][11] - The adjusted EBITDA for H1 2025 was 1.101 billion yuan, reflecting a decrease of 3.4% year-on-year, with an adjusted EBITDA margin of 15.7% [5][11] - The company plans to distribute an interim dividend of 0.19 HKD per share, totaling 109 million yuan [5] Business Segment Performance - ANC business grew by 5.0% year-on-year in H1 2025, with significant growth in the Chinese mainland market, particularly through the Swisse brand [5][11] - BNC business saw a 2.9% increase year-on-year, with the ultra-premium infant formula market share reaching a historical high of 15.9% in the Chinese mainland [5][11] - PNC business reported a 9.6% year-on-year increase, with improved profitability driven by margin enhancements [5][11] Future Outlook - The company expects continued growth in the second half of 2025, with Swisse focusing on product innovation and online channel expansion [6][11] - The BNC segment is anticipated to benefit from the transition to new national standards and the ongoing recovery in infant formula sales [6][11] - PNC is expected to maintain its growth trajectory, particularly in the North American market [6][11] Financial Projections - EPS estimates for 2025, 2026, and 2027 are projected at 0.56, 1.03, and 1.26 yuan respectively [11] - The company’s total revenue is expected to reach 14.083 billion yuan in 2025, with a year-on-year growth of 8% [7][11]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company has shown strong recovery as a market leader, with impressive performance in its financial results for the first half of 2025, achieving a revenue of 25.622 billion RMB, a year-on-year increase of 15.6%, and a net profit attributable to shareholders of 7.622 billion RMB, up 22.1% year-on-year [1][3] - The packaging water business is gradually recovering from previous public sentiment issues, with revenue of 9.443 billion RMB, a 10.7% increase year-on-year, and a net profit of 3.347 billion RMB, reflecting a 22.0% growth [1][3] - The beverage segment, particularly tea and juice, has shown remarkable growth, with revenues of 10.089 billion RMB and 2.898 billion RMB, respectively, marking increases of 19.7% and 13.6% year-on-year [2][3] Financial Performance Summary - For the first half of 2025, the company achieved a gross margin of 60.3%, an increase of 1.55 percentage points year-on-year, primarily due to lower costs of PET, cartons, and sugar [3] - The company’s selling expenses decreased, leading to a net profit margin of 29.7%, up 1.61 percentage points year-on-year [3] - The projected net profit for 2025-2027 is expected to grow by 20.4%, 16.7%, and 15.7%, reaching 14.6 billion RMB, 17.0 billion RMB, and 19.7 billion RMB, respectively [3] Business Segment Analysis - The packaging water segment is expected to continue its recovery, supported by the company's strong brand and market influence [3] - The beverage segment is focused on innovation and the development of major products, contributing to overall industry growth [3] - The company plans to explore overseas markets to create new growth opportunities [3]

Investment Rating - The report maintains an "Outperform" rating for Hansoh Pharma with a target price of HKD 44.32, based on a current price of HKD 37.66 [2][7]. Core Insights - Hansoh Pharma's revenue for 1H25 reached CNY 7.4 billion, representing a year-on-year growth of 14%, with innovative drug sales contributing CNY 6.1 billion, up 22% year-on-year. Collaboration revenue was CNY 1.66 billion, an 18% increase year-on-year [3][12]. - The management has raised the full-year revenue guidance to high double digits, reflecting strong performance and expectations for continued growth [3][12]. Financial Performance - Revenue projections for FY25, FY26, and FY27 have been adjusted to CNY 14.7 billion, CNY 16.0 billion, and CNY 17.7 billion respectively, with net profit estimates of CNY 5.0 billion, CNY 5.1 billion, and CNY 5.7 billion [7][13]. - The gross profit margin (GPM) for 1H25 was reported at 91.1%, remaining stable compared to the previous year [3][12]. Segment Performance - The oncology segment generated CNY 4.5 billion, accounting for 61% of total revenue, driven by the strong sales of Aumolertinib, which received approvals for new indications [4][15]. - The anti-infection segment contributed CNY 740 million, while the central nervous system segment generated CNY 770 million, and the metabolism and other diseases segment accounted for CNY 1.4 billion [15][13]. Key Catalysts - Upcoming catalysts for Hansoh Pharma include the inclusion of Aumolertinib in the National Reimbursement Drug List (NRDL) and the anticipated approval of its combination with chemotherapy for NSCLC [4][15]. - The company has received approximately CNY 850 million in milestone revenue, exceeding previous management guidance, indicating a potential for sustainable revenue growth from future milestones [15][13].

Investment Rating - The report maintains a "Buy" rating for the company [2][6]. Core Insights - The company achieved a revenue of $1.23 billion in H1 2025, representing a year-on-year growth of 12.4%, and a net profit of $100 million, up 17.0% year-on-year. The interim dividend was set at 16.3 HK cents per share, totaling $60 million, with a payout ratio of 60% [4][6]. - The company is expected to maintain strong order growth in the short to medium term due to its diversified product categories and supply chain advantages, which enhance core customer penetration and increase market share among new sports clients. Profitability is anticipated to improve through order structure optimization, integration, and automation, leading to a potential increase in valuation as growth materializes [2][4]. Summary by Sections Revenue Performance - The company reported a revenue of $1.23 billion in H1 2025, with significant growth across various product categories: leisure (+11%), outdoor sports (+12%), denim (+10%), underwear (+10%), and sweaters (+29%). The revenue growth was driven by the company's ability to meet diverse downstream demands and enhance core customer penetration [7][4]. Profitability - The gross margin improved by 0.2 percentage points to 19.7% in H1 2025, with notable increases in leisure and underwear segments. The net profit margin also saw a slight increase of 0.3 percentage points to 8%, supported by effective cost management and a reduction in the effective tax rate [7][4]. Future Outlook - The company is projected to achieve net profits of $230 million, $260 million, and $300 million for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 16%, 14%, and 13%. The expected price-to-earnings ratios for these years are 11, 9, and 8 times, with a projected dividend yield of 5.5% in 2025 under a 60% payout assumption [2][9].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported a significant improvement in net profit, achieving a total revenue of 783 million yuan, a year-on-year increase of 26.8%, and a net profit attributable to shareholders of 1.511 billion yuan, with net assets increasing by 112.6% to 2.611 billion yuan [1] Revenue and Profit Forecast - The company is expected to see total revenue growth from 1.705 billion yuan in 2025 to 2.624 billion yuan in 2027, with year-on-year growth rates of 30%, 26%, and 22% respectively [7] - The net profit attributable to shareholders is projected to rise dramatically to 1.399 billion yuan in 2025, with a staggering year-on-year growth of 931.8% [7] Business Performance - The digital payment service revenue increased by 26.2% to 684 million yuan, with global payment revenue growing by 27.0% to 473 million yuan, reflecting a robust performance in the cross-border e-commerce export market [7] - The company has obtained 65 global payment licenses, enhancing its compliance barriers and local service capabilities [7] Cost and Expense Management - Sales expenses rose by 18.3% to 129 million yuan, primarily due to increased promotional activities for customer acquisition [7] - Management expenses increased by 3.3% to 300 million yuan, reflecting strategic investments in blockchain technology [7] Strategic Initiatives - The company is actively expanding into the Web3.0 space and enhancing its digital financial infrastructure, including the launch of virtual bank cards and partnerships to explore stablecoin applications in cross-border payments [7]

Investment Rating - The investment rating for China Communication Services is "Buy" and is maintained [9]. Core Views - The company reported a 3.4% year-on-year increase in operating revenue for the first half of 2025, amounting to RMB 76.939 billion, with a net profit of RMB 2.129 billion, reflecting a 0.2% growth [2][6]. - The gross margin is at 10.3%, while the net profit margin stands at 2.8% [2][6]. - Non-operator revenue has surpassed half of the total revenue for the first time, indicating stronger resilience in revenue performance [9]. - The company has effectively managed its SG&A expenses, resulting in a decrease in expense ratios, which has helped mitigate pressure on gross margins [9]. - Cash flow remains strong, and the dividend payout ratio has been steadily increasing, suggesting attractive current valuations [9]. Summary by Sections Financial Performance - In 2025H1, the revenue breakdown shows TIS business revenue at RMB 38.272 billion (up 1.6%), BPO business revenue at RMB 22.383 billion (up 1.0%), and ACO business revenue at RMB 16.284 billion (up 11.7%) [9]. - Operator revenue totaled RMB 38.203 billion, down 4.55%, while customer revenue reached RMB 36.585 billion, up 12.9% [9]. Business Development - New contracts signed in 2025H1 exceeded RMB 106 billion, a slight decline of about 2% year-on-year, with strategic emerging businesses contributing over RMB 42 billion, marking a growth of over 10% [9]. - The distribution of new contracts shows operators account for about 31%, while customer segments represent approximately 65% [9]. Market Outlook - The capital expenditure from major operators has been cautious, but there is an expectation for acceleration in the second half of the year, which could support further growth for the company [9]. - The first half of 2025 saw capital expenditures from China Mobile, China Telecom, and China Unicom at RMB 58.4 billion, RMB 34.2 billion, and RMB 20.2 billion, respectively, reflecting declines of 8.8%, 27.5%, and 15.5% year-on-year [9].

Investment Rating - The report maintains a "Buy" rating for the company [3][7]. Core Insights - The company continues to reduce losses in Q2 2025, with strong sales growth in core products and an improving expense ratio, leading to stable overall performance and cash reserves [2][7]. - The global peak sales estimate for the key product, Tai Tasi Pu, has been raised to $3.1 billion based on excellent clinical data [2]. - The target price has been adjusted upwards to HKD 103, reflecting the company's performance in the first half of 2025 and anticipated contributions from new business development collaborations [2][8]. Financial Performance Summary - Revenue for 1H25 increased by 47.6% year-on-year to RMB 1.09 billion, driven by strong sales of Tai Tasi Pu and Vidisizumab [7]. - The gross profit margin improved by 7.3 percentage points to 84.4%, with further optimization in expense ratios [7]. - The company has a robust cash reserve of RMB 1.48 billion and an additional bank credit line of RMB 2.7 billion [7]. Earnings Forecast Changes - Revenue forecasts for 2025 and 2026 have been increased by 25% and 3% respectively, while the 2027 revenue forecast has been decreased by 14% [6]. - The gross profit for 2025 is projected at RMB 2.602 billion, reflecting a 38% increase from previous estimates [6]. - The net profit for 2027 is expected to rise by 87% to RMB 742 million, indicating a significant turnaround [6]. Valuation Model - The DCF valuation model estimates the equity value at RMB 52.776 billion, translating to a per-share value of HKD 103 [8].

Investment Rating - The report assigns a "Buy" rating for the company, marking its initial coverage [2][3]. Core Insights - The company possesses a globally scarce humanized only heavy chain antibody platform, establishing a core competitive barrier [2]. - The platform's value enhances business development (BD) potential, with recognized R&D capabilities and stable collaborations with multinational corporations (MNCs) like AstraZeneca [2][3]. - The company is expected to see significant profit growth due to its strong pipeline in the autoimmune sector and multiple ongoing projects [3]. Summary by Sections 1. R&D Platform Technology Value - The company focuses on innovative drug development and commercialization in oncology and immune diseases, leveraging its unique HCAb technology platform [12]. - Established in 2016, the company has developed proprietary platforms for generating human monoclonal antibodies [13]. 2. HCAb Harbour Mice: Scarce Humanized Only Heavy Chain Antibody Platform - The HCAb platform is the only patented humanized only heavy chain antibody development platform globally, capable of producing various antibody forms [31][38]. - The platform's unique advantages include high solubility, stability, and the ability to generate diverse antibody libraries [34]. 3. Strong BD Capabilities with MNC Collaborations - The company has established a robust BD strategy, focusing on early-stage pipeline collaborations with major pharmaceutical companies [62]. - Significant partnerships include a global strategic collaboration with AstraZeneca, enhancing the company's market position and financial stability [63][70]. 4. Competitive Product Lines in Autoimmune Sector - The company is set to launch its product, Bartoli monoclonal antibody, which targets myasthenia gravis, in collaboration with CSPC [3]. - Another promising pipeline candidate, HBM9378, is in Phase II clinical trials for asthma and COPD, indicating strong market potential [3]. 5. Earnings Forecast and Valuation - The company is projected to achieve revenues of $154.08 million and net profits of $81.75 million by 2025, with a target price of HKD 18.80 [3].